|
Remibrutinib (Blinded) Clinical Trials
2 actively recruiting trials across 2 locations
No change since May 2026
Also known as: LOU064, LOU64
Pipeline
Phase 3: 2
Top Sponsors
- Novartis Pharmaceuticals2
Indications
- Secondary Progressive Multiple Sclerosis (SPMS)1
- Multiple Sclerosis1
- Generalized Myasthenia Gravis1
- Cancer1
Birmingham, Alabama1 trial
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Alabama Neurology Associates PC
Phase 3
Phoenix, Arizona1 trial
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
Neuromuscular Research Center
Phase 3
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.